ZEJULA in BRCAm patients
Dr Domenica Lorusso discusses ZEJULA in BRCAm patients.
Not a healthcare professional? Visit our Public site
Not a healthcare professional? Visit our Public site
59
ZEJULA is the only approved 1L once-daily maintenance for patients with aOC.1–3 Explore videos from world-leading oncologists on their experience of using ZEJULA in clinical practice.
Contraindications:
Hypersensitivity to the active substances or to any of the excipients.
Special warnings and precautions:
Haematologic adverse reactions (thrombocytopenia, anaemia, neutropenia) have been reported. Discontinue if a patient develops severe persistent haematologic toxicity including pancytopenia that does not resolve within 28 days following interruption.
Use with caution in patients on anticoagulants and medicinal products known to reduce the thrombocyte count hypertension, hepatic impairment.
Pregnancy/contraception:
Should not be used during pregnancy.
Adverse Events:
Very common: Urinary Tract Infections, thrombocytopenia, anaemia, neutropenia, leukopenia, decreased appetite, insomnia.
Please refer to the local prescribing information for a more detailed safety information.
1L, first-line; aOC, advanced ovarian cancer; BRCA, breast cancer susceptibility gene; BRCAm, BRCA-mutation; BRCAwt, BRCA wild-type; HRd, homologous recombination deficient.
For more information, please refer to the prescribing information or contact GlaxoSmithKline via gcc.medinfo@gsk.com
To report Adverse Event/s associated with the use of GSK product/s, please contact us via
gulf.safety@gsk.com
To report quality complaint/s associated with the use of GSK product/s, please contact us via
Gulf.ProductQualityComplaints@gsk.com
Department of Pharmacovigilance & Drug Information |
دائرة التيقظ و المعلومات الدوائية مركز سلامة الدواء وزارة الصحة, سلطنة عمان هاتف: 0096822357687 / 0096822357690 0096822358489 :فاكس pharma-vigil@moh.gov.om :البريد االكتروني www.moh.gov.om : الموقع االكتروني |
Trademarks are owned by or licensed to the GSK group of companies.
©2024 GSK group of companies or its licensor. All rights reserved.
PM-RCH-NRP-SRCH-240001 | August 2024